Literature DB >> 35015686

Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies.

Jessie Bourcier1, Omar Abdel-Wahab1.   

Abstract

SUMMARY: In this issue of Blood Cancer Discovery, Zheng and colleagues identify that alternative RNA splicing of CD22 within B-cell acute lymphoblastic leukemia can result in antigen escape from CD22-targeted immunotherapies. Drug-resistant isoforms of CD22 exist within leukemic cells pretreatment and can influence response to the CD22-directed antibody-drug conjugate inotuzumab ozogamicin, the immunotoxin moxetumomab pasudotox, as well as anti-CD22 chimeric antigen receptor T cells. See related article by Zheng et al., p. 103 (7). ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35015686      PMCID： PMC9245399          DOI： 10.1158/2643-3230.BCD-21-0200

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  9 in total

1.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Authors:  Rebecca Gardner; David Wu; Sindhu Cherian; Min Fang; Laïla-Aïcha Hanafi; Olivia Finney; Hannah Smithers; Michael C Jensen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

2.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

3.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Authors:  Fatih M Uckun; Patricia Goodman; Hong Ma; Ilker Dibirdik; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-14       Impact factor: 11.205

4.  CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.

Authors:  Mohamad Hamieh; Anton Dobrin; Annalisa Cabriolu; Sjoukje J C van der Stegen; Theodoros Giavridis; Jorge Mansilla-Soto; Justin Eyquem; Zeguo Zhao; Benjamin M Whitlock; Matthew M Miele; Zhuoning Li; Kristen M Cunanan; Morgan Huse; Ronald C Hendrickson; Xiuyan Wang; Isabelle Rivière; Michel Sadelain
Journal:  Nature       Date:  2019-03-27       Impact factor: 49.962

5.  Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.

Authors:  Sarah K Tasian; Andrei Thomas-Tikhonenko; Sisi Zheng; Elisabeth Gillespie; Ammar S Naqvi; Katharina E Hayer; Zhiwei Ang; Manuel Torres-Diz; Mathieu Quesnel-Vallières; David A Hottman; Asen Bagashev; John Chukinas; Carolin Schmidt; Mukta Asnani; Rawan Shraim; Deanne M Taylor; Susan R Rheingold; Maureen M O'Brien; Nathan Singh; Kristen W Lynch; Marco Ruella; Yoseph Barash
Journal:  Blood Cancer Discov       Date:  2022-03-01

6.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Authors:  Marco Ruella; Jun Xu; David M Barrett; Joseph A Fraietta; Tyler J Reich; David E Ambrose; Michael Klichinsky; Olga Shestova; Prachi R Patel; Irina Kulikovskaya; Farzana Nazimuddin; Vijay G Bhoj; Elena J Orlando; Terry J Fry; Hans Bitter; Shannon L Maude; Bruce L Levine; Christopher L Nobles; Frederic D Bushman; Regina M Young; John Scholler; Saar I Gill; Carl H June; Stephan A Grupp; Simon F Lacey; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

7.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Authors:  Elena J Orlando; Xia Han; Catherine Tribouley; Patricia A Wood; Rebecca J Leary; Markus Riester; John E Levine; Muna Qayed; Stephan A Grupp; Michael Boyer; Barbara De Moerloose; Eneida R Nemecek; Henrique Bittencourt; Hidefumi Hiramatsu; Jochen Buechner; Stella M Davies; Michael R Verneris; Kevin Nguyen; Jennifer L Brogdon; Hans Bitter; Michael Morrissey; Piotr Pierog; Serafino Pantano; Jeffrey A Engelman; Wendy Winckler
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

8.  Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Authors:  Mehmet Kemal Samur; Mariateresa Fulciniti; Anil Aktas Samur; Abdul Hamid Bazarbachi; Yu-Tzu Tai; Rao Prabhala; Alejandro Alonso; Adam S Sperling; Timothy Campbell; Fabio Petrocca; Kristen Hege; Shari Kaiser; Hervé Avet Loiseau; Kenneth C Anderson; Nikhil C Munshi
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

9.  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Authors:  Terry J Fry; Nirali N Shah; Rimas J Orentas; Maryalice Stetler-Stevenson; Constance M Yuan; Sneha Ramakrishna; Pamela Wolters; Staci Martin; Cindy Delbrook; Bonnie Yates; Haneen Shalabi; Thomas J Fountaine; Jack F Shern; Robbie G Majzner; David F Stroncek; Marianna Sabatino; Yang Feng; Dimiter S Dimitrov; Ling Zhang; Sang Nguyen; Haiying Qin; Boro Dropulic; Daniel W Lee; Crystal L Mackall
Journal:  Nat Med       Date:  2017-11-20       Impact factor: 53.440
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.